Traws Pharma (TRAW) Competitors $1.79 +0.13 (+7.51%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.76 -0.03 (-1.40%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. LVTX, RENB, CALC, MDCX, MRSN, OKUR, XCUR, EPIX, XLO, and ESLAShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include LAVA Therapeutics (LVTX), Renovaro (RENB), CalciMedica (CALC), Medicus Pharma (MDCX), Mersana Therapeutics (MRSN), OnKure Therapeutics (OKUR), Exicure (XCUR), ESSA Pharma (EPIX), Xilio Therapeutics (XLO), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Its Competitors LAVA Therapeutics Renovaro CalciMedica Medicus Pharma Mersana Therapeutics OnKure Therapeutics Exicure ESSA Pharma Xilio Therapeutics Estrella Immunopharma Traws Pharma (NASDAQ:TRAW) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment. Which has more risk and volatility, TRAW or LVTX? Traws Pharma has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Which has higher earnings and valuation, TRAW or LVTX? LAVA Therapeutics has higher revenue and earnings than Traws Pharma. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$230K54.95-$166.52M$88.830.02LAVA Therapeutics$11.98M3.45-$25.11M-$1.05-1.50 Do institutionals & insiders have more ownership in TRAW or LVTX? 8.0% of Traws Pharma shares are held by institutional investors. 13.6% of Traws Pharma shares are held by insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is TRAW or LVTX more profitable? Traws Pharma has a net margin of 3,028.25% compared to LAVA Therapeutics' net margin of 0.00%. LAVA Therapeutics' return on equity of -106.29% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma3,028.25% -1,812.48% 512.72% LAVA Therapeutics N/A -106.29%-38.24% Does the media refer more to TRAW or LVTX? In the previous week, LAVA Therapeutics had 1 more articles in the media than Traws Pharma. MarketBeat recorded 2 mentions for LAVA Therapeutics and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 0.07 beat LAVA Therapeutics' score of -0.50 indicating that Traws Pharma is being referred to more favorably in the media. Company Overall Sentiment Traws Pharma Neutral LAVA Therapeutics Negative Do analysts rate TRAW or LVTX? LAVA Therapeutics has a consensus target price of $2.69, indicating a potential upside of 71.02%. Given LAVA Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LAVA Therapeutics is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00LAVA Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryTraws Pharma beats LAVA Therapeutics on 9 of the 15 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.76M$2.56B$5.77B$9.91BDividend YieldN/A50.34%6.71%4.52%P/E Ratio0.0223.0375.5426.08Price / Sales54.95569.11480.4288.33Price / CashN/A167.8736.9659.01Price / Book-0.215.5011.446.09Net Income-$166.52M$32.95M$3.28B$266.14M7 Day Performance27.86%2.86%0.96%0.34%1 Month Performance17.76%8.61%7.82%4.42%1 Year PerformanceN/A1.86%62.64%26.17% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.6958 of 5 stars$1.79+7.5%N/AN/A$11.76M$230K0.0217Short Interest ↑LVTXLAVA Therapeutics1.4154 of 5 stars$1.52+0.7%$2.69+76.6%-4.3%$39.72M$11.98M-1.4560Short Interest ↑RENBRenovaro0.6872 of 5 stars$0.23+0.6%N/A-63.8%$39.40MN/A-0.3020News CoverageShort Interest ↑CALCCalciMedica3.2642 of 5 stars$2.87+2.9%$16.00+457.5%-40.2%$38.98MN/A-1.7930Positive NewsShort Interest ↓Gap UpMDCXMedicus Pharma1.75 of 5 stars$2.04-6.0%$23.50+1,052.0%N/A$38.66MN/A-1.52N/ANews CoverageAnalyst ForecastMRSNMersana Therapeutics3.85 of 5 stars$7.65flat$56.60+639.9%-80.8%$38.18M$40.50M-0.52150OKUROnKure Therapeutics2.9471 of 5 stars$2.75-2.5%$32.33+1,075.8%N/A$38.09MN/A-0.57N/AXCURExicure1.7365 of 5 stars$5.89-0.5%N/A+154.0%$37.40M$500K-1.5250Positive NewsShort Interest ↓EPIXESSA Pharma2.9977 of 5 stars$0.26-66.4%$2.00+660.2%-95.9%$37.08MN/A-0.4750Dividend AnnouncementHigh Trading VolumeXLOXilio Therapeutics2.5199 of 5 stars$0.700.0%$3.00+328.6%-9.5%$36.28M$6.34M-0.9270ESLAEstrella Immunopharma2.2266 of 5 stars$0.97+0.1%$16.00+1,550.3%-0.9%$35.92MN/A-3.73N/AGap Down Related Companies and Tools Related Companies LAVA Therapeutics Competitors Renovaro Competitors CalciMedica Competitors Medicus Pharma Competitors Mersana Therapeutics Competitors OnKure Therapeutics Competitors Exicure Competitors ESSA Pharma Competitors Xilio Therapeutics Competitors Estrella Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
